|
Wide nose
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Well Differentiated Oligodendroglioma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
However, analyses according to histological subtypes revealed a statistically significant increased risk of oligodendroglioma in association with SMARCA2 rs2296212 (OR = 4.05, 95% CI = 1.11-14.80, P = 0.030, q = 0.08) and rs4741651 (OR = 4.68, 95% CI = 1.43-15.30, P = 0.011, q = 0.08) and SMARCA4 rs11672232 (OR = 1.90, 95% CI = 1.01-3.58, P = 0.048, q = 0.08) and rs12232780 (OR = 2.14, 95% CI = 1.06-4.33, P = 0.035, q = 0.08).
|
23276717 |
2013 |
|
Visual Impairment
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Virus Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The levels of truncated SMARCA2 or SMARCA4 strongly correlate with the degree of cell damage and death observed after virus infection.
|
29848589 |
2018 |
|
Vascular Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
These include gene fusions in vascular neoplasms (FOSB, CAMTA1 and TFE3), round cell sarcomas (BCOR, DUX4 and WT1), and fibroblastic/myofibroblastic tumors (STAT6, ALK and Pan-TRK); amplifications in well-differentiated and dedifferentiated liposarcomas (MDM2 and CDK4); and deletions in several aggressive neoplasms (SMARCB1 and SMARCA4).
|
30382607 |
2019 |
|
Vascular inflammations
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Endothelial-specific deletion of Brg1/Brm ameliorated vascular inflammation and HPH in mice.
|
24042015 |
2013 |
|
Vascular calcification
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Consequently, our study demonstrates that Smarca4 is involved in hyperphosphorus-induced VC.
|
30973285 |
2019 |
|
Uterine Corpus Sarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
SMARCA4-deficient Uterine Sarcoma and Undifferentiated Endometrial Carcinoma are Distinct Clinicopathologic Entities.
|
31567195 |
2020 |
|
Ureteral obstruction
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Endothelial-specific deletion of Brahma-related gene 1 (BRG1) assuages unilateral ureteral obstruction induced renal injury in mice.
|
31349970 |
2019 |
|
Undifferentiated carcinoma of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
SMARCA4-deficient undifferentiated carcinoma of the ovary (small cell carcinoma, hypercalcemic type): clinicopathologic and immunohistochemical study of 3 cases.
|
26123103 |
2015 |
|
Undifferentiated carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma.
|
29700418 |
2018 |
|
Undifferentiated carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Alterations in the IDH2-wild-type sinonasal undifferentiated carcinomas included SMARCA4 loss-of-function with confirmed loss of immunohistochemical expression, NOTCH1 gain-of-function, and TET2 loss-of-function.
|
28084339 |
2017 |
|
Undifferentiated carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Thoracic SMARCA4-deficient sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas.
|
31751681 |
2020 |
|
Undifferentiated carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
We analyzed 24 grade 3 uterine endometrioid adenocarcinomas and 2 undifferentiated carcinomas for immunohistochemical expression of SMARCB1 and SMARCA4.
|
25920939 |
2015 |
|
Undifferentiated carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
SMARCA4 (BRG1), which encodes another member of the SWI/SNF pathway, and which is mutated in almost all small-cell carcinomas of the ovary, hypercalcaemic type, has been investigated in endometrial carcinomas, and mutations with resultant loss of immunohistochemical staining have been demonstrated in some endometrial undifferentiated carcinomas/dedifferentiated carcinomas.
|
27656868 |
2017 |
|
Undifferentiated carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry for claudin-4 was performed on 130 neoplasms, including 90 soft tissue tumors with epithelioid morphology and/or SMARCB1 deficiency (20 epithelioid sarcomas (10 conventional, 10 proximal-type); 10 epithelioid angiosarcomas; 10 epithelioid hemangioendotheliomas; 15 epithelioid malignant peripheral nerve sheath tumors; 10 malignant rhabdoid tumors; 15 myoepithelial carcinomas; 10 biphasic synovial sarcomas), 10 ovarian clear cell carcinomas, 10 ovarian small cell carcinomas of hypercalcemic type, and 20 SWI/SNF complex-deficient undifferentiated carcinomas (14 SMARCB1 deficient and 6 SMARCA4 deficient, including rhabdoid carcinomas of various sites and sinonasal carcinomas).
|
28084340 |
2017 |
|
Tumor Progression
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
These data strongly support the model that BRG1 may function as a tumor suppressor and strengthen the hypothesis that the regulation of gene expression through chromatin remodeling is critical for cancer progression.
|
11085541 |
2000 |
|
Tumor Progression
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
To determine how BRG1 loss fuels tumor progression in NSCLC, molecular profiling was performed after restoration of BRG1 expression or treatment with a histone deacetylase inhibitor or a DNA methyltransferase (DNMT) inhibitor in a BRG1-deficient NSCLC cells.
|
24445599 |
2014 |
|
Tumor Progression
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
However, BRG1 expression did not correlate with Gleason score/International Society of Urological Pathology (ISUP) Grade Group, indicating it is an independent predictor of tumor progression/patient outcome.
|
30667054 |
2019 |
|
Tumor Progression
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Here, we found that BRG1 is upregulated in HCC and that its level significantly correlates with cancer progression in HCC patients.
|
29352111 |
2018 |
|
Tumor Initiation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In mature duct cells, Brg1 inhibits the dedifferentiation that precedes neoplastic transformation, thus attenuating tumor initiation.
|
25792600 |
2015 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Our results identify ZEB1/BRG1 as a new transcriptional mechanism regulating E-cadherin expression and epithelial-to-mesenchymal transdifferentiation that may be involved during the initial stages of tumor invasion.
|
20418909 |
2010 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Statistical analysis revealed that BRM expression was related to tumor size, T factor, M factor, lymphatic invasion and stage BRG1 expression to histology and stage BAF180 expression to tumor size and BAF47 expression to lymphatic invasion, respectively.
|
23229642 |
2013 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We studied the role of BRG1 in glioma cell migration and invasion by cell migration assay and matrigel invasion assay.
|
22362300 |
2012 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Collectively, these findings show that M2 macrophages induce colorectal cancer cells' migration and invasion and provide significant plasticity of BRG1 expression in response to tumor microenvironments during malignant progression.
|
30401711 |
2019 |